Evommune
Develops chronic-inflammation therapies centered on EVO756 and EVO301 clinical programs.
$13.23
After-hours close+0.01 (+0.08%)
At close$13.22(−1.93%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 95.27%Insiders —
Shares outstanding 36.29M · Float 19.21M · 52.9% free float
Institutions13F, as of Mar 31, 2026
84 holders · 34.58M shares · 37 new positions · 63 increased · 11 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Eqt Fund Management S.A R.L. | 4.93M | 13.58% | 0 | May 14, 2026 |
| Ra Capital Management, L.P. | 3.49M | 9.63% | +35.9K | May 15, 2026 |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.93M | 5.31% | 0 | May 14, 2026 |
| Andera Partners | 1.90M | 5.23% | 0 | May 11, 2026 |
| RTW Investments, LP | 1.50M | 4.14% | +218.6K | May 15, 2026 |
| JPMorgan Chase & Co | 1.46M | 4.02% | +150.5K | May 13, 2026 |
| Bioimpact Capital LLC | 1.46M | 4.01% | +1.34M | May 15, 2026 |
| Nan Fung Group Holdings Ltd | 1.44M | 3.97% | 0 | May 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.